The relative expression levels of the two esophageal cancer cells in the CAP treatment group for 5 min were less than 50% of the control group, indicating that CAP may inhibit the expression of glutamine transporter SLC1A5 in esophageal cancer cells by suppressing the expression of related genes such as K-Ras. This evidence concerns the gene KRAS and esophageal cancer.